SMi reports: West Pharmaceutical Services to Host a Free Exclusive Webinar on Prefilled Syringe Elastomer Components High-Quality Solutions for Sensitive Molecules, taking place on 16 th July 2020.

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference 2023 will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for ...

INCHEON, South Korea, May 24, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ® ...

Hadlima is supplied in prefilled syringes, autoinjectors, and single-dose vials as both a high-concentration (40mg/0.4mL) and low-concentration (40mg/0.8mL) formulation. The interchangeability ...

8 HADLIMA was first approved by the FDA in 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and autoinjector. The high-concentration (40 mg/0.4 mL) formulation of ...

Emgality comes in a prefilled pen or syringe for preventing migraine and a prefilled syringe for treating cluster headaches. The way you inject the drug depends on whether it’s in a syringe or a ...

The cannabidiol (CBD) world can feel huge and complicated, but products like CBD gummies make it more approachable for some folks. CBD gummies are easy to dose, portable, and discreet. They also ...

With the safePICO self-fill blood gas syringe, you can improve your mixing and get results you can trust. Mixing ball helps you obtain a homogeneous sample SafeTIPCAP minimizes the risk of blood ...

14 days Prescribing information Etanercept powder Enbrel (Immunex Corporation [Amgen and Wyeth Pharmaceuticals]) 7 days Manufacturer Etanercept prefilled syringe Enbrel (Immunex Corporation [Amgen ...

Sibeprenlimab would be offered in a prefilled syringe for subcutaneous injection. The PDUFA target action date is Nov. 28, 2025. The FDA has accepted for priority review the biologics license ...